<p>高風險投資者對 Insmed (NASDAQ: INSM) 持悲觀態度，零售交易者需要注意這一點。
\這一活動通過 Benzinga 對公開可用期權數據的跟蹤引起了我們的注意。這些投資者的身份尚不確定，但 INSM 的如此重大變動通常意味着有人掌握了內部信息。</p>
<p>今天，Benzinga 的期權掃描儀發現了 8 筆 Insmed 的期權交易。這並不是一個典型的模式。</p>
<p>這些主要交易者的情緒分歧，12% 看漲，75% 看跌。在我們識別的所有期權中，有一筆看跌期權，金額為 27,207 美元，和 7 筆看漲期權，總計 347,874 美元。</p>
<h3>預測價格區間</h3>
<p>在評估交易量和未平倉合約後，顯然主要市場參與者關注 Insmed 的價格區間在 32.5 美元到 200.0 美元之間，涵蓋了過去三個月。</p>
<h3>交易量與未平倉合約發展</h3>
<p>檢查交易量和未平倉合約為股票研究提供了重要見解。這些信息對於評估 Insmed 在特定行權價格的期權流動性和興趣水平至關重要。以下是過去一個月 Insmed 重大交易中看漲和看跌期權的交易量和未平倉合約趨勢快照，行權價格範圍在 32.5 美元到 200.0 美元之間。</p>
<h3>Insmed 看漲和看跌期權交易量：30 天概覽</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766775710_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="期權看漲圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766775710_0.png"/></p>
<h3>值得注意的期權活動：</h3>
<table>
<thead>
<tr>
<th><strong>符號</strong></th>
<th><strong>看跌/看漲</strong></th>
<th><strong>交易類型</strong></th>
<th><strong>情緒</strong></th>
<th><strong>到期日</strong></th>
<th><strong>賣出價</strong></th>
<th><strong>買入價</strong></th>
<th><strong>價格</strong></th>
<th><strong>行權價格</strong></th>
<th><strong>總交易價格</strong></th>
<th align="right"><strong>未平倉合約</strong></th>
<th align="right"><strong>交易量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>INSM</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>02/20/26</td>
<td>$7.6</td>
<td>$7.0</td>
<td>$6.79</td>
<td>$200.00</td>
<td>$95.9K</td>
<td align="right">246</td>
<td align="right">137</td>
</tr>
<tr>
<td>INSM</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>01/16/26</td>
<td>$146.0</td>
<td>$143.3</td>
<td>$146.0</td>
<td>$32.50</td>
<td>$73.0K</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td>INSM</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>02/20/26</td>
<td>$8.9</td>
<td>$7.0</td>
<td>$7.06</td>
<td>$200.00</td>
<td>$58.1K</td>
<td align="right">246</td>
<td align="right">249</td>
</tr>
<tr>
<td>INSM</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>02/20/26</td>
<td>$7.2</td>
<td>$7.0</td>
<td>$6.97</td>
<td>$200.00</td>
<td>$34.9K</td>
<td align="right">246</td>
<td align="right">364</td>
</tr>
<tr>
<td>INSM</td>
<td>看漲</td>
<td>掃描</td>
<td>中立</td>
<td>02/20/26</td>
<td>$7.0</td>
<td>$6.5</td>
<td>$6.76</td>
<td>$200.00</td>
<td>$33.9K</td>
<td align="right">246</td>
<td align="right">471</td>
</tr>
</tbody>
</table>
<h3>關於 Insmed</h3>
<p>Insmed Inc 是一家生物製藥公司，致力於改善嚴重和罕見疾病患者的生活。該公司的首個商業產品是 ARIKAYCE（阿米卡星脂質體吸入懸液），已在美國獲得批准，用於治療結核分枝桿菌複合體（MAC）肺病，作為成人患者有限或沒有替代治療選擇的抗菌藥物組合的一部分。它還在開發 Brensocatib，一種用於支氣管擴張症和其他中性粒細胞介導疾病的口服可逆性二肽基肽酶 1 抑制劑，以及用於與間質性肺病和肺動脈高壓相關的肺動脈高壓的吸入性特雷普斯汀前藥。</p>
<h3>Insmed 當前市場狀況</h3>
<ul>
<li>目前交易量為 476,194，INSM 的價格上漲了 1.45%，現為 180.0 美元。</li>
<li>RSI 指標顯示該股票可能接近超賣狀態。</li>
<li>預計收益發布將在 55 天后。</li>
</ul>
<h3>專業分析師對 Insmed 的評級</h3>
<p>5 位市場專家最近對該股票發佈了評級，目標價格共識為 220.2 美元。</p>
<p><strong>在短短 20 天內將 1000 美元變成 1270 美元？</strong></p>
<p>一位擁有 20 年經驗的期權交易員透露了他的單行圖表技術，顯示何時買入和賣出。複製他的交易，平均每 20 天獲得 27% 的利潤。點擊這裏獲取訪問權限。
* 一位來自高盛的分析師決定維持對 Insmed 的買入評級，目前目標價格為 225 美元。
* 一位來自 Cantor Fitzgerald 的分析師堅持對 Insmed 的增持評級，維持目標價格為 230 美元。
* 一位來自 Guggenheim 的分析師堅持對 Insmed 的買入評級，維持目標價格為 221 美元。
* 一位來自 RBC Capital 的分析師維持對 Insmed 的跑贏大盤評級，目標價格為 195 美元。
* 一位來自 HC Wainwright &amp; Co. 的分析師維持對 Insmed 的買入評級，目標價格為 230 美元。</p>
<p>與僅交易股票相比，期權是一種風險更高的資產，但它們具有更高的利潤潛力。嚴肅的期權交易者通過每天學習、逐步進出交易、關注多個指標以及密切關注市場來管理這種風險。</p>
<p>如果您想及時瞭解 Insmed 的最新期權交易，Benzinga Pro 提供實時期權交易警報。</p>

INSM

<p>高風險投資者對 Insmed（NASDAQ:INSM）表現出看跌情緒，75% 的期權交易為看跌，12% 為看漲。Benzinga 的掃描器識別出 8 筆交易，關注價格區間為 32.5 美元至 200.0 美元。Insmed 的股票上漲 1.45%，現報 180.0 美元，分析師維持積極評級，目標價格在 195 美元至 230 美元之間。期權交易風險較高，但提供更高的利潤潛力。Benzinga Pro 提供 Insmed 期權交易的實時警報</p>

<p>High-rolling investors have positioned themselves bearish on Insmed (NASDAQ: INSM), and it's important for retail traders to take note.
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in INSM often signals that someone has privileged information.</p>
<div class="lb-trans"><p>高風險投資者對 Insmed (NASDAQ: INSM) 持悲觀態度，零售交易者需要注意這一點。
\這一活動通過 Benzinga 對公開可用期權數據的跟蹤引起了我們的注意。這些投資者的身份尚不確定，但 INSM 的如此重大變動通常意味着有人掌握了內部信息。</p>
</div><p>Today, Benzinga's options scanner spotted 8 options trades for Insmed. This is not a typical pattern.</p>
<div class="lb-trans"><p>今天，Benzinga 的期權掃描儀發現了 8 筆 Insmed 的期權交易。這並不是一個典型的模式。</p>
</div><p>The sentiment among these major traders is split, with 12% bullish and 75% bearish. Among all the options we identified, there was one put, amounting to $27,207, and 7 calls, totaling $347,874.</p>
<div class="lb-trans"><p>這些主要交易者的情緒分歧，12% 看漲，75% 看跌。在我們識別的所有期權中，有一筆看跌期權，金額為 27,207 美元，和 7 筆看漲期權，總計 347,874 美元。</p>
</div><h3>Predicted Price Range</h3>
<div class="lb-trans"><h3>預測價格區間</h3>
</div><p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $32.5 and $200.0 for Insmed, spanning the last three months.</p>
<div class="lb-trans"><p>在評估交易量和未平倉合約後，顯然主要市場參與者關注 Insmed 的價格區間在 32.5 美元到 200.0 美元之間，涵蓋了過去三個月。</p>
</div><h3>Volume &amp; Open Interest Development</h3>
<div class="lb-trans"><h3>交易量與未平倉合約發展</h3>
</div><p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Insmed's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Insmed's significant trades, within a strike price range of $32.5 to $200.0, over the past month.</p>
<div class="lb-trans"><p>檢查交易量和未平倉合約為股票研究提供了重要見解。這些信息對於評估 Insmed 在特定行權價格的期權流動性和興趣水平至關重要。以下是過去一個月 Insmed 重大交易中看漲和看跌期權的交易量和未平倉合約趨勢快照，行權價格範圍在 32.5 美元到 200.0 美元之間。</p>
</div><h3>Insmed Call and Put Volume: 30-Day Overview</h3>
<div class="lb-trans"><h3>Insmed 看漲和看跌期權交易量：30 天概覽</h3>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1766775710_0.png" alt="Options Call Chart" original-src="https://www.benzinga.com/files/images/story/2025/1766775710_0.png"/></p>
<h3>Noteworthy Options Activity:</h3>
<div class="lb-trans"><h3>值得注意的期權活動：</h3>
</div><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$7.6</td>
<td>$7.0</td>
<td>$6.79</td>
<td>$200.00</td>
<td>$95.9K</td>
<td align="right">246</td>
<td align="right">137</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$146.0</td>
<td>$143.3</td>
<td>$146.0</td>
<td>$32.50</td>
<td>$73.0K</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$8.9</td>
<td>$7.0</td>
<td>$7.06</td>
<td>$200.00</td>
<td>$58.1K</td>
<td align="right">246</td>
<td align="right">249</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$7.2</td>
<td>$7.0</td>
<td>$6.97</td>
<td>$200.00</td>
<td>$34.9K</td>
<td align="right">246</td>
<td align="right">364</td>
</tr>
<tr>
<td>INSM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>02/20/26</td>
<td>$7.0</td>
<td>$6.5</td>
<td>$6.76</td>
<td>$200.00</td>
<td>$33.9K</td>
<td align="right">246</td>
<td align="right">471</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>符號</strong></th>
<th><strong>看跌/看漲</strong></th>
<th><strong>交易類型</strong></th>
<th><strong>情緒</strong></th>
<th><strong>到期日</strong></th>
<th><strong>賣出價</strong></th>
<th><strong>買入價</strong></th>
<th><strong>價格</strong></th>
<th><strong>行權價格</strong></th>
<th><strong>總交易價格</strong></th>
<th align="right"><strong>未平倉合約</strong></th>
<th align="right"><strong>交易量</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>INSM</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>02/20/26</td>
<td>$7.6</td>
<td>$7.0</td>
<td>$6.79</td>
<td>$200.00</td>
<td>$95.9K</td>
<td align="right">246</td>
<td align="right">137</td>
</tr>
<tr>
<td>INSM</td>
<td>看漲</td>
<td>交易</td>
<td>看漲</td>
<td>01/16/26</td>
<td>$146.0</td>
<td>$143.3</td>
<td>$146.0</td>
<td>$32.50</td>
<td>$73.0K</td>
<td align="right">5</td>
<td align="right">0</td>
</tr>
<tr>
<td>INSM</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>02/20/26</td>
<td>$8.9</td>
<td>$7.0</td>
<td>$7.06</td>
<td>$200.00</td>
<td>$58.1K</td>
<td align="right">246</td>
<td align="right">249</td>
</tr>
<tr>
<td>INSM</td>
<td>看漲</td>
<td>掃描</td>
<td>看跌</td>
<td>02/20/26</td>
<td>$7.2</td>
<td>$7.0</td>
<td>$6.97</td>
<td>$200.00</td>
<td>$34.9K</td>
<td align="right">246</td>
<td align="right">364</td>
</tr>
<tr>
<td>INSM</td>
<td>看漲</td>
<td>掃描</td>
<td>中立</td>
<td>02/20/26</td>
<td>$7.0</td>
<td>$6.5</td>
<td>$6.76</td>
<td>$200.00</td>
<td>$33.9K</td>
<td align="right">246</td>
<td align="right">471</td>
</tr>
</tbody>
</table>
</div><h3>About Insmed</h3>
<div class="lb-trans"><h3>關於 Insmed</h3>
</div><p>Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.</p>
<div class="lb-trans"><p>Insmed Inc 是一家生物製藥公司，致力於改善嚴重和罕見疾病患者的生活。該公司的首個商業產品是 ARIKAYCE（阿米卡星脂質體吸入懸液），已在美國獲得批准，用於治療結核分枝桿菌複合體（MAC）肺病，作為成人患者有限或沒有替代治療選擇的抗菌藥物組合的一部分。它還在開發 Brensocatib，一種用於支氣管擴張症和其他中性粒細胞介導疾病的口服可逆性二肽基肽酶 1 抑制劑，以及用於與間質性肺病和肺動脈高壓相關的肺動脈高壓的吸入性特雷普斯汀前藥。</p>
</div><h3>Present Market Standing of Insmed</h3>
<div class="lb-trans"><h3>Insmed 當前市場狀況</h3>
</div><ul>
<li>Currently trading with a volume of 476,194, the INSM's price is up by 1.45%, now at $180.0.</li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 55 days.</li>
</ul>
<div class="lb-trans"><ul>
<li>目前交易量為 476,194，INSM 的價格上漲了 1.45%，現為 180.0 美元。</li>
<li>RSI 指標顯示該股票可能接近超賣狀態。</li>
<li>預計收益發布將在 55 天后。</li>
</ul>
</div><h3>Professional Analyst Ratings for Insmed</h3>
<div class="lb-trans"><h3>專業分析師對 Insmed 的評級</h3>
</div><p>5 market experts have recently issued ratings for this stock, with a consensus target price of $220.2.</p>
<div class="lb-trans"><p>5 位市場專家最近對該股票發佈了評級，目標價格共識為 220.2 美元。</p>
</div><p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<div class="lb-trans"><p><strong>在短短 20 天內將 1000 美元變成 1270 美元？</strong></p>
</div><p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.
* An analyst from Goldman Sachs has decided to maintain their Buy rating on Insmed, which currently sits at a price target of $225.
* An analyst from Cantor Fitzgerald persists with their Overweight rating on Insmed, maintaining a target price of $230.
* An analyst from Guggenheim persists with their Buy rating on Insmed, maintaining a target price of $221.
* Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Insmed, targeting a price of $195.
* Maintaining their stance, an analyst from HC Wainwright &amp; Co. continues to hold a Buy rating for Insmed, targeting a price of $230.</p>
<div class="lb-trans"><p>一位擁有 20 年經驗的期權交易員透露了他的單行圖表技術，顯示何時買入和賣出。複製他的交易，平均每 20 天獲得 27% 的利潤。點擊這裏獲取訪問權限。
* 一位來自高盛的分析師決定維持對 Insmed 的買入評級，目前目標價格為 225 美元。
* 一位來自 Cantor Fitzgerald 的分析師堅持對 Insmed 的增持評級，維持目標價格為 230 美元。
* 一位來自 Guggenheim 的分析師堅持對 Insmed 的買入評級，維持目標價格為 221 美元。
* 一位來自 RBC Capital 的分析師維持對 Insmed 的跑贏大盤評級，目標價格為 195 美元。
* 一位來自 HC Wainwright &amp; Co. 的分析師維持對 Insmed 的買入評級，目標價格為 230 美元。</p>
</div><p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<div class="lb-trans"><p>與僅交易股票相比，期權是一種風險更高的資產，但它們具有更高的利潤潛力。嚴肅的期權交易者通過每天學習、逐步進出交易、關注多個指標以及密切關注市場來管理這種風險。</p>
</div><p>If you want to stay updated on the latest options trades for Insmed, Benzinga Pro gives you real-time options trades alerts.</p>
<div class="lb-trans"><p>如果您想及時瞭解 Insmed 的最新期權交易，Benzinga Pro 提供實時期權交易警報。</p>
</div>

深入分析 Insmed 的期權市場動態